Trial Profile
Study to evaluate the prevalence of resistance mutations and the association of polymorphism with the virological outcome in patients receiving Raltegravir-containing anti-retroviral regimens
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jun 2017
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 29 Jun 2017 New trial record
- 05 Jun 2017 Results presented at the ASM Microbe 2017